Hemophilia A - 41 Studies Found Recruiting : Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A : Acquired Hemophilia A : 2015-10-29 : Biological: OBIZUR Treating physician will determine treatment regimen, frequency of laboratory and clin No longer available : Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies : Acquired Hemophilia A : 2013-10-21 : Biological: OBI-1 Other Name: B-Domain Deleted Recombinant Porcine Factor VIII Terminated : Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A : Hemophilia A : 2006-03-23 : Drug: Rituxan Acquired Hemophi Completed : Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A : Hemophilia A : 2010-08-06 : Biological: OBI-1 Intravenous infusion Completed : Inhibitor Development in Patients With Hemophilia A Undergoing Surgery : Hemophilia A : 2012-04-04 Completed : Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A : Hemophilia A : 2009-04-09 : Biological: Biostate® [SP] Completed : Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery : Hemophilia A : 2004-09-28 : Drug: ReFacto Completed : Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A : Hemophilia A : 2005-09-11 : Drug: ReFacto Drug: Advante Completed : Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients : Hemophilia A : 2009-06-04 : Biological: Moroctocog alfa ( AF-CC) Recruiting : Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A : Haemophilia A : 2013-03-13 : Biological: Optivate 500IU Next >>>